BR0213043A - Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração - Google Patents

Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração

Info

Publication number
BR0213043A
BR0213043A BR0213043-2A BR0213043A BR0213043A BR 0213043 A BR0213043 A BR 0213043A BR 0213043 A BR0213043 A BR 0213043A BR 0213043 A BR0213043 A BR 0213043A
Authority
BR
Brazil
Prior art keywords
subject
myocardial
treating
preventing
compound
Prior art date
Application number
BR0213043-2A
Other languages
English (en)
Inventor
Mark Anderson
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BR0213043A publication Critical patent/BR0213043A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

"MéTODOS DE TRATAR OU PREVENIR DISFUNçãO CONTRáTIL MIOCáRDICA APóS INFARTO DO MIOCáRDIO EM UM SUJEITO, DE TRATAR OU PREVENIR CARDIOMIOPATIA DILATADA EM UM SUJEITO E DE INCREMENTAR CONTRATILIDADE MIOCáRDICA EM UM SUJEITO, ANIMAL TRANSGêNICO, E, MéTODO DE IDENTIFICAR UM COMPOSTO QUE PODE TRATAR DOENçA ESTRUTURAL DO CORAçãO". A presente invenção proporciona um método de tratar doença estrutural do coração em um sujeito, compreendendo administrar uma quantidade efetiva de um inibidor de CaMKIIa ao sujeito, com o que a administração do inibidor trata a doença estrutural do coração no sujeito. Proporciona-se também modelos animais transgênicos para tratar doença estrutural do coração. Proporciona-se adicionalmente um meio de selecionar um composto que pode tratar doença estrutural do coração.
BR0213043-2A 2001-10-01 2002-10-01 Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração BR0213043A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US32801001P 2001-10-08 2001-10-08
PCT/US2002/031496 WO2003029428A2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Publications (1)

Publication Number Publication Date
BR0213043A true BR0213043A (pt) 2004-10-05

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213043-2A BR0213043A (pt) 2001-10-01 2002-10-01 Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração

Country Status (14)

Country Link
US (2) US7320959B2 (pt)
EP (1) EP1439849A4 (pt)
JP (1) JP2005504829A (pt)
KR (1) KR20040045041A (pt)
CN (1) CN1599622A (pt)
AU (1) AU2002341938B2 (pt)
BR (1) BR0213043A (pt)
CA (1) CA2462443A1 (pt)
IL (1) IL161231A0 (pt)
MX (1) MXPA04003040A (pt)
NO (1) NO20041331L (pt)
NZ (1) NZ532327A (pt)
PL (1) PL369104A1 (pt)
WO (1) WO2003029428A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052420A (zh) * 2004-11-02 2007-10-10 大日本住友制药株式会社 用于治疗自体免疫疾病的并用药
JP5415520B2 (ja) * 2008-04-09 2014-02-12 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最大酸素消費量低下の予測のためのプロ−エンドセリン−１
US8841423B2 (en) * 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
WO2010135676A1 (en) * 2009-05-22 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
WO2014138212A1 (en) 2013-03-06 2014-09-12 Allosteros Therapeutics, Inc. CaMKII INHIBITORS AND USES THEREOF
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
AU2015311730A1 (en) 2014-09-05 2017-04-20 Allosteros Therapeutics, Inc Camkii inhibitors and uses thereof
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
CN112972447B (zh) * 2021-03-02 2022-09-23 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (pt) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JP2001509808A (ja) * 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
JP2963986B2 (ja) * 1997-11-19 1999-10-18 工業技術院長 カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Also Published As

Publication number Publication date
EP1439849A2 (en) 2004-07-28
AU2002341938B2 (en) 2007-08-30
US7320959B2 (en) 2008-01-22
CA2462443A1 (en) 2003-04-10
NZ532327A (en) 2005-10-28
KR20040045041A (ko) 2004-05-31
EP1439849A4 (en) 2005-09-28
WO2003029428A2 (en) 2003-04-10
NO20041331D0 (no) 2004-03-31
MXPA04003040A (es) 2004-07-15
PL369104A1 (en) 2005-04-18
US20040266675A1 (en) 2004-12-30
NO20041331L (no) 2004-05-28
US7632815B2 (en) 2009-12-15
JP2005504829A (ja) 2005-02-17
WO2003029428A3 (en) 2003-10-30
IL161231A0 (en) 2004-09-27
CN1599622A (zh) 2005-03-23
WO2003029428A8 (en) 2004-04-22
US20090011989A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
BR0213043A (pt) Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração
ECSP066599A (es) Método para el tratamiento de la enfermedad asociada con adamts-5
BR0005276A (pt) Compostos para o tratamento de disfução sexual feminina
DE69820265D1 (de) Für den vogelembryo geeignete multivalente impfstoffe
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
Titball et al. Burkholderia pseudomallei: animal models of infection
BRPI0509139A (pt) composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor
ATE419014T1 (de) Verbindungen zur behandlung der ischaemischen gewebe
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
BR112022019085A2 (pt) Uso de agentes para tratamento de condições respiratórias
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
BR0112659A (pt) Processo para o tratamento de secura vaginal ou disfunção sexual em mulheres durante ou depois da menopausa e utilização do composto (diaminoidroxi)toremifeno ou de um sal, éster ou metabolito farmaceuticamente aceitável do mesmo
EA199901075A1 (ru) Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста
NO930893D0 (no) Ultralydformidlet administrering av forbindelser i akvatiske dyr
Grahn et al. Blockade of alpha1 adrenoreceptors in the dorsal raphe nucleus prevents enhanced conditioned fear and impaired escape performance following uncontrollable stressor exposure in rats
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
Wojtkiewicz et al. Inflammation-induced changes in the chemical coding pattern of colon-projecting neurons in the inferior mesenteric ganglia of the pig
BR9916391A (pt) Compostos de triazineona para o tratamento de doenças causadas por sarcosiste, neopora e toxoplasma
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.